Press "Enter" to skip to content

Organicell and Oklahoma State University Sign Agreement to Study Zofin ™ in Respiratory Diseases Caused by Viral Infections with Pandemic Potential

MIAMI – ( BUSINESS WIRE ) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has signed an agreement with Oklahoma State University to evaluate Zofin ™ for the treatment of respiratory diseases. caused by viral infections with pandemic potential. This study site follows the Company's previous announcement of an agreement with the Centers for Disease Control and Prevention ("CDC") to conduct research to determine the anti-inflammatory and anti-infective effectiveness of Zofin ™ in experimental models of influenza infection. .

The ongoing COVID-19 pandemic has infected more than 5 million people worldwide and caused more than 300,000 deaths in 188 countries. Additionally, the CDC estimates between 39 and 55 million flu-related illnesses and more than 60,000 deaths due to flu. The observed illnesses and fatalities are primarily due to the lack of known effective prophylactic and antiviral vaccines to attenuate viruses.

In this agreement, Organicell will supply Oklahoma State University with its main compound, Zofin ™, which is an acellular material derived from human amniotic fluid. This therapeutic treatment based on nanoparticles derived from extracellular vesicles will be evaluated based on its ability to induce antiviral and / or immunomodulatory activity against viral infections with pandemic potential, since there is an unmet need for non-toxic and effective therapeutic approaches to deal with current and impending pandemics. .

“Organicell is dedicated to continuing the research of regenerative therapies for illnesses with unmet needs. We are delighted to partner with Oklahoma State University and the CDC in the study of Zofin ™ for viral infections of pandemic proportions. One year after the pandemic, it has shown us the importance of research aimed at the development of biological products, ”said Albert Mitrani, Executive Director of Organicell.

"We are excited to partner with Oklahoma State University and the CDC to investigate how nanoparticles derived from extracellular vesicles, in Zofin ™, will affect the antiviral and / or immunomodulatory activity of viral infections with pandemic potential." Dr. Mari Mitrani, Scientific Director of Organicell.

About Zofin ™:

Zofin is an acellular biological therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines and chemokines, as well as other extracellular vesicles / nanoparticles derived from perinatal tissues. Zofin ™ is currently being tested in a phase I / II randomized, double-blind, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin ™ for the treatment of moderate to COVID-related SARS. 19 versus placebo.


Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company harnessing the power of exosomes to develop innovative biological therapies for the treatment of degenerative diseases. The Company's proprietary products are derived from perinatal sources and are manufactured to retain natural exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer, and Dr. Mari Mitrani, Chief Scientific Officer. For more information, visit[19459006


Some of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Stock Exchange Act of 1934, as amended (the "Stock Market Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believe", "expect", "potential" or Similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks and uncertainties, and these expectations may turn out to be incorrect. We remind you that actual results may vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, ability to retain key personnel, safety, efficacy, and product acceptance success commercialization of any new products or technologies, the success of clinical programs, the ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including the pricing of products, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including risk factors discussed in the Company's periodic reports filed with the SEC and are available on the website of l to SEC ( You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell does not intend and specifically disclaims any duty to update the information in this press release.

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *